# Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

> **NCT00110929** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 850 (—)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** AMG 073

## Key facts

- **NCT ID:** NCT00110929
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 850 (—)
- **Last updated:** 2010-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110929, "Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00110929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*